Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04979247
PHASE4

Intravenous Oliceridine and Opioid-related Complications

Sponsor: The Cleveland Clinic

View on ClinicalTrials.gov

Summary

The investigator will evaluate the side effects of oliceridine.

Official title: Intravenous Oliceridine and Opioid-related Complications: VOLITION: A Multicenter Pilot Cohort Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

204

Start Date

2021-09-15

Completion Date

2024-01-10

Last Updated

2026-05-14

Healthy Volunteers

No

Conditions

Interventions

DRUG

Oliceridine

Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.

Locations (3)

Wake Forest Bapist Medical Center

Winston-Salem, North Carolina, United States

Cleveland Clinic Fairview Hospital

Cleveland, Ohio, United States

Cleveland Clinic Main Campus

Cleveland, Ohio, United States